Immuneering Corporation Class A (IMRX)
NASDAQ: IMRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IMRX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $218.90M
- EPS (TTM)
- -$0.92
- Dividend yield
- None
- 52-week range
- 3.29 – 8.48
- Day range
- 3.29 – 3.54
- Volume / Avg
- 1.45M / 747.66K
- Beta
- —
- Shares outstanding
- 64.76M
52-week range
IMRX stock today
Immuneering (IMRX) closed at $3.38 on Nov 20, down 2.03% (-$0.07), versus the S&P 500's 3.70% decline. At this level, IMRX sits near the bottom of its 52-week range of $3.29 to $8.48: 60.1% below the high, set on Jan 7, 2026 and 2.8% above the low. IMRX is down 48.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 53.7%.
Immuneering has posted a net loss over the last twelve months (EPS of -$0.92), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Immuneering
Company profileImmuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Benjamin J. Zeskind M.B.A., Ph.D.
- Headquarters
- Cambridge, MA
- Employees
- 65
- IPO year
- 2021
- Website
- immuneering.com
Financial highlights
Full financialsImmuneering reported a net loss of $56.0 million, compared with a loss of $61.0 million a year earlier. Diluted earnings per share came in at -$1.27.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | $0 | $316.95K | $2.08M |
| Growth | — | — | -100.00% | -84.76% | -10.02% |
| Net income | $-56.02M | $-61.04M | $-53.47M | $-50.51M | $-33.54M |
| EPS (diluted) | $-1.27 | $-2.04 | $-1.88 | $-1.91 | $-2.46 |
Analyst forecast
ForecastConsensus (7 analysts)
strong_buy
Avg. price target
$17.00+402.96%
- Strong buy 2
- Buy 5
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 11, 2026
- EPS actual vs est.
- $-0.37 vs $-0.29
- Surprise
- -27.59%
IMRX news
All IMRX news- Immuneering Releases Data Validating Atebimetinib As MAPK Backbone In Pancreatic & Thyroid CancerNasdaqIMRX, BF.A
- Immuneering Presents Additional Data Demonstrating Atebimetinib’s Broad Potential as a Backbone for Combination Therapy in Pancreatic CancerGlobeNewswire
- Immuneering Presents Data That Supports Expanding the Clinical Evaluation of Atebimetinib to Anaplastic Thyroid CancerGlobeNewswire
- Astellas, Immuneering Enter Pancreatic Cancer Trial CollaborationNasdaq
- Immuneering Announces New Potentially Registrational Phase 2 Trial Evaluating Atebimetinib with Chemotherapy in Anaplastic Thyroid CancerGlobeNewswire
- Immuneering Corporation Appoints Grant C. Bogle to Board of Directors on November 9, 2026Nasdaq
- Immuneering Appoints Accomplished Commercial Leader Grant Bogle to Board of DirectorsGlobeNewswire
- Atebimetinib Combinations with Anti-PD1 Cured 50% of Mice in a RAS-Mutant Colorectal Cancer Model and Nearly Doubled Survival in a RAS-Mutant Lung Cancer Model; New Data Presented at SITC 2026GlobeNewswire
Immuneering peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| RCKTRocket Pharmaceuticals Inc. | 1.95 | -7.58% | $217.74M | vs IMRX |
| KROSKeros Therapeutics Inc. | 11.08 | -2.72% | $217.44M | vs IMRX |
| PYXSPyxis Oncology Inc. | 1.81 | +7.74% | $216.49M | vs IMRX |
| ENTAEnanta Pharmaceuticals Inc. | 7.62 | -4.51% | $222.19M | vs IMRX |
| ARCTArcturus Therapeutics Holdings Inc. | 7.45 | -1.97% | $214.73M | vs IMRX |
| CYPHCypherpunk Technologies Inc. | 1.41 | -18.02% | $210.15M | vs IMRX |
| VNDAVanda Pharmaceuticals Inc. | 3.45 | -6.13% | $208.32M | vs IMRX |
| FTHFaeth Therapeutics Inc. | 7.88 | -9.32% | $203.65M | vs IMRX |
Indexes, lists and sector
Immuneering stock FAQ
What is Immuneering's stock price today?
IMRX last traded at $3.38 as of Nov 20, 4:00 PM EST, down 2.03% on the day. Prices are delayed at least 15 minutes.
Who is Immuneering's CEO?
Dr. Benjamin J. Zeskind M.B.A., Ph.D. is the chief executive officer of Immuneering Corporation Class A, which has about 65 employees.
What is the IMRX 52-week high?
The 52-week high for IMRX is $8.48 and the 52-week low is $3.29. The stock is currently 60.1% below its high.